ELTX

$3.15+$0.09 (+2.94%)prev close

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$80.4M

26M shares

52-week range

$2.66 – $16.00

4% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change$-14.99

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$20M	—	$-2.07	$-2.29–$-1.81	—	3
2027	$0	-100.0%	$-2.43	$-2.63–$-2.22	—	2
2028	$0	—	$-2.70	$-3.30–$-2.10	—	2
2029	$0	—	$-4.00	$-4.00–$-4.00	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 3 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-13	$-0.54	$-0.43	+20.0%
2026-05-11	$-0.49	$-0.65	-32.7%
2026-03-12	$-0.47	$-0.49	-4.3%
2025-11-13	$-0.62	$-0.60	+3.2%
2025-08-07	$-0.69	$-0.66	+4.3%
2025-05-13	$-0.67	$-0.87	-29.9%
2025-03-31	$-0.94	$-1.02	-8.5%
2024-11-13	$-0.81

DCF fair valuemodel estimate

Intrinsic value

$0.23

Price

$3.15

Implied downside

-93%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ELTXElicio Therapeutics, Inc.	$3.15	+2.94%	$60M	—
ACTUActuate Therapeutics Inc	$0.98	-0.48%	$23M	—
APLTApplied Therapeutics, Inc.	$0.10	+0.00%	$15M	—
CRBPCorbus Pharmaceuticals Holdings, Inc.	$10.08	+3.28%	$187M	—
CRDFCardiff Oncology, Inc.	$0.98	-0.66%

Elicio Therapeutics, Inc. Common Stock

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

www.elicio.com

Employees: 33
IPO / List date: Jun 2, 2023
HQ: BOSTON, MA

Held by traders on TradeandTell

No one on the platform currently holds ELTX.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	121,631	$1.3M

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded ELTX yet.

$ELTX chatter on StockTwits

J@rimzzzBullish14h
$ELTX waiting on good news😪
View on StockTwits ↗
M@justiceforb_853d
$ELTX nice update for P1.
View on StockTwits ↗
Gregg@Golferhack12Aug 5
$ELTX today earnings?
View on StockTwits ↗
Blunt Force Options@BluntForceOptionsBullishAug 5
$ELTX The multi-week descending triangle has officially resolved to the upside. Near-term targets sit at $3.50–$4.00. Holding the $2.90–$3.00 breakout floor keeps momentum fully intact for the next leg up. Holding our position and watching how price action materializes. Giddy up!
View on StockTwits ↗
humdime@humdimeAug 4
$ELTX It seems Merck is planning a sac-TMT + Keytruda trial as the Keytruda patent cliff approaches. Looks like they re searching for the next winning CPI combination.
View on StockTwits ↗
Blunt Force Options@BluntForceOptionsBullishJul 31
$ELTX Initiated a 1/3 starter position at $2.88 - $2.93 today while also selling $2.50 puts to further lower our effective cost basis. In my view, the recent collapse down to near 52-wk lows ($2.66) creates a compelling risk/reward disconnect. The stock took a double beating over the last six weeks... first dropping 70% when Phase 2 AMPLIFY-7P missed its primary ITT endpoint due to a trial baseline imbalance, and then getting hit with a dilutive $15M direct offering at $3.43. What makes this setup intriguing now, IMO, is the follow-up data released on June 17th showing three confirmed complete responses in microsatellite-stable pancreatic cancer when paired with checkpoint inhibitors... an outcome that's very rare in this disease (0–8% historical CR rates). With 84% of R0 resected patients showing clear clinical benefit and $15M in fresh institutional capital backing their Phase 1 combo trial, the post-offering wash-out has handed us a deep discount on a proven T-cell priming engine. Moving forward, I’ll be scaling into this position accordingly as the setup develops, keeping in mind that the upside potential at these depressed levels is significant. As always, NFA. Please do your own work/DD. (Daily chart attached for reference)
View on StockTwits ↗
Paperhandsfordays@PaperhandsfordaysJul 29
$ELTX so what’s up with this ? Absolutely no motion
View on StockTwits ↗
Candelingproblem@ckjamesstBullishJul 24
$INHD $ELTX $TLRY $SPY $SAFT Next on Squeez list is PCSA. Moved 30% in 5 days something big about to show up. Gl buy some before squeez to 16-22-35-50+
View on StockTwits ↗
Barclay mullins@BarclayMullinsJul 23
$ELTX just found this guy Looks interesting
View on StockTwits ↗
J@rimzzzBullishJul 21
$ELTX watching
View on StockTwits ↗
Grant Forman@nhyujm6Jul 16
$ELTX Very interesting - Moti Investments, a Gulf-based, no-name investor, just took a >5% concentrated position in ELTX. It reads as someone with a specific thesis — putting real conviction behind it via the cheapest entry point available (a discounted private placement) rather than buying in the open market at the post-rally price.
View on StockTwits ↗
D3L@24DV4NC3DBullishJul 16
$ELTX ⚡️WHAT DID I SAY?!⚡️ STOCK OF THE DAY - VOLUME >>> GREAT SETUP <<< >>>>> #LISTEN! <<<<< 🎯 XXX% ON TAP >> CONTINUATION LIKELY! << >>>>>>> LISTEN! <<<<<<<
View on StockTwits ↗
M@justiceforb_85Jul 15
$ELTX ELI-002 7P has value but problem is current cash position and pending P1 readout. Would be great if we received some further updates on additional patients who received chemo/CPI and whether there are more complete responses.
View on StockTwits ↗
Trade4Keeps@Trade4KeepsJul 15
$ELTX back down again
View on StockTwits ↗
L@WoooehooBearishJul 13
$ELTX let this sink to <$2 like it should please
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.